Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2005-09-06
2005-09-06
Leith, Patricia (Department: 1654)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S094100, C424S094600, C424S094610, C514S002600
Reexamination Certificate
active
06939542
ABSTRACT:
A thimerosal-free hyaluronidase preparation wherein the preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also disclosed is a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of the eye, said method comprising the step of contacting at least one hemorrhage-clearing enzyme (e.g., a β-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase or protein kinase) with the vitreous humor in an amount which is effective to cause accelerated clearance of blood therefrom.
REFERENCES:
patent: 3728223 (1973-04-01), Kaneko et al.
patent: 3869548 (1975-03-01), Dabis
patent: 3945889 (1976-03-01), Mima et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4174389 (1979-11-01), Cope
patent: 4258134 (1981-03-01), Yoshida et al.
patent: 4474751 (1984-10-01), Haslam et al.
patent: 4490351 (1984-12-01), Clark, Jr.
patent: 4757089 (1988-07-01), Epstein
patent: 4820516 (1989-04-01), Sawyer et al.
patent: 4861760 (1989-08-01), Mazuel et al.
patent: 4871742 (1989-10-01), Bonne et al.
patent: 4897349 (1990-01-01), Swann et al.
patent: 4904594 (1990-02-01), Karlstam
patent: 5061627 (1991-10-01), Olsen et al.
patent: 5077033 (1991-12-01), Viegas et al.
patent: 5166331 (1992-11-01), Della Valle et al.
patent: 5252318 (1993-10-01), Joshi et al.
patent: 5260059 (1993-11-01), Acott et al.
patent: 5270051 (1993-12-01), Harris
patent: 5292509 (1994-03-01), Hageman
patent: 5300295 (1994-04-01), Viegas et al.
patent: 5316926 (1994-05-01), Brown et al.
patent: 5318780 (1994-06-01), Viegas et al.
patent: 5326761 (1994-07-01), Rozier
patent: 5366964 (1994-11-01), Lindstrom et al.
patent: 5496726 (1996-03-01), Park et al.
patent: 5593877 (1997-01-01), King
patent: 5747027 (1998-05-01), Stern et al.
patent: 5756552 (1998-05-01), Takeuchi et al.
patent: 5827721 (1998-10-01), Stern et al.
patent: 5866120 (1999-02-01), Karageozian et al.
patent: 6039943 (2000-03-01), Karageozian et al.
patent: 6123938 (2000-09-01), Stern et al.
patent: RE37336 (2001-08-01), Weigel et al.
patent: 6551590 (2003-04-01), Karageozian et al.
patent: 6610292 (2003-08-01), Karageozian et al.
patent: 0 193 330 (1986-09-01), None
patent: 0625579 (1994-11-01), None
patent: 0892045 (1999-01-01), None
patent: 1048725 (2000-11-01), None
patent: WO 97/18835 (1997-05-01), None
patent: WO 00/77221 (2000-12-01), None
Antoszyk, et al., “An Experimental Model of Preretinal Neovascularization in the Rabbit” Investigative Ophthalmology & Visual Science, 32 : 46-52 (1991).
Belkin, et al., “Urokinase-Treatment of Fresh Laser Irradiation-Induced Vitreous Hemorrhage”, Ophthalmologica, Basel, 187 : 152-156 (1983).
Benson, et al. (1971)Vitreous Hemorrhage.Survey of Ophthalmology 5:297-311.
Boyer, et al. (1958)Studies on Simulated Vitreous Hemorrhages.A.M.A. Archives of Ophthalmology 59:333-336.
Borowski, et al. “Influence of Hyaluronidaze on Vitreous Haemorrhages”, Klin. Oczna 87: 129-30 (1985).
Bramsen, T., “The Effect of Urokinase on Central Corneal Thickness and Vitreous Haemorrhage”, ACTA Ophthalmologica, 56 1006-1012 (1978).
Calbiochem 1994/95, Catalog 1994/95 (6 pages).
Chapman-Smith, et al., “Urokinase in the Management of Vitreous Haemorrhage”, British Journal of Ophthalmology, 61 : 500-505 (1977).
Cleary,e t al., “Intravitreal Urokinase in the Treatment of Vitreous Hemorrhage”, Transactions of the Ophthalmological Societies of the United Kingdom, 94 : 587-590 (1974).
Coleman, et al., “The Role of Vitrectomy in Traumatic Vitreopathy”, Symposium: Pars Plana Vitrectomy, 81 :OP406-OP413, (1976).
Coles, et al., “Vitrectomy in Intraocular Trauma”, Archives of Ophthamology, 87 : 621-628 (1972).
Constable, et al., “Pathology of Vitreous Membranes and the Effect of Hemmorrhage and New Vessels on the Vitreous”, Transactions of the Ophthalmological Societies of the United Kingdom, 95 : 382-386 (1975).
Dugmore, et al., “Intravitreal Urokinase in the Treatment of Vitreous Hemorrhage”, American Journal of Ophthalmology, 75 : 779-781 (1973).
“Enzyme Nomenclature-Enzyme List”, International Union of Biochemistry and Molecular Biology, prepared for NC-IUBMB by Edwin C. Webb, pp. 350, (1992).
Forrester, et al., “Resolutions of Intravitreal Clots by Urokinase”, Lancet, 2 : 179 (1973b).
Forrester, et al., “Lytic Therapy in Vitreous Hemorrhage”, Transactions of the Ophthalmological Societies Of The United Kingdom, 94 : 582-586 (1974).
Forrester, et al., Total Vitreous Haemorrhage A Method of Treatment, Transactions of the Ophthalmological Societies of the United Kingdom, 94 : 992-999 (1974).
Forrester, et al., “Intravitreal Fibrinolysis on Experimental Vitreous Hemorrhage”, Experimental Eye Research, 22 : 181-188 (1976).
Forrester, et al., “The Effect of Fibrinolytic Inhibition in the Resolution of Experimental Vitreous Haemorrhage”, American Journal of Ophthalmology, 84 : 810-814 (1977).
Forrester, et al., “The Pathology of Vitreous Hemorrhage. I Gross and Histological Appearances”, Archives of Ophthalmology, 90 : 703-710 (1978).
Forrester, et al., “The Pathology of Vitreous Hemorrhage, II. Ultrastructure”, Archives Of Ophthalmology, 57 : 2368-2374 (1979).
Foulds, et al., Effect of Intravitreal Hyalruondise on the Clearance of Tritiated Water from the Vitreous to the Choroid British Journal of Ophthalmology, 69 : 529-532 (1985).
Gharley, et al., “Closed Vitreous Surgery. XVII. Results and Complications of Pars Plana Vitrectomy”, Archives of Ophthalmology, 98 : 1248-1252 (1980).
Gibbons, et al., “Retinal Damage from Suprathreshold Q-switch Laser Exposure”, Health Physics, 35 : 461-469 (1978).
Gottlieb, et al., “The Safety of Intravitreal Hyaluronidase”, Investigative Ophthalmology Visual Science, 31 : 2345-2352 (1990).
Greer, et al., “A Study of Stimulated Vitreous Hemorrhage Using Labeled Blood”, Archives Of Ophthalmology, 79 : 755-758 (1988).
Hageman, et al., “Chondroitin 6-Sulfate Glycosaminoglycan is a Major Constituent of Primate Cone Photoreceptor Matrix Sheaths”, Dept. of Anatomy and Cell Biology, Univ. of Southern California School of Medicine, Los Angeles, Current Eye Research, 6 : 639-646 (1987).
Harooni, et al. (1998)Efficacy and Safety of Enzymatic Posterior Vitreous Detachment by Intravitreal Injection of Hyaluronidase,Retina 18:116-22.
Harooni, et al. (1996)Efficacy and Safety of Vitreous Liquefaction by Intravitreal Injection of Hyaluronidase.Abstract Investigative Ophthalmology and Visual Science, Annual Meeting Fort Lauderdale, FL. Apr. 21 through Apr. 26, 1996.
Holmes,e t al., “Intravitreal Urokinase in the Management of Vitreous Haemorrhage”, Transcript of Ophthalmological Societies of the United Kingdom, 94 : 591-596 (1974).
Kang, et al. (1995)Induction of Bitreolysis and Vitreous Detachment with Hyaluronidase and Perfluoroproopane Gas.Korean J. Ophthalmol. 9:69-78.
Karageozian, et al., “Hyaluronidase in intravireal use; evaluation of toxicity in animal model”, Investigative Ophthalmology & Visual Science, 38(4), abstract XP002076958, (May 15, 1997).
Kim, et al., “The Influence of Enzymes and Inflammation on Absorption of Experimentally Induced Vitreous Hemorrhage”, Dept. of Ophthalmology, Korea Univ. Medical Journal, 9(1): 87-97 (1972).
Knepper, et al. (1984)Exogenous Hyaluronidases and Degradation of Hyaluronic Acid in the Rabbit Eye.Investigative Ophthalmology & Visual Science 25:286-293.
Koziol, et al., “Urokinase in Experimental Vitreous Hemorrhage”, Ophthalmic Surgery, 6 : 79-82 (1975).
LaNauze, et al. (1982)Chemotaxis in Vitreous Hemorrhage: An Experimental Study.Exp. Eye Res. 34:803-813.
Linder, et al., “Hyaluronidase Activity in Cultures of an Anaerobic Strain of Corynebacteria and Some Properties of the Enzyme”, Scand. J.
Aragon Gabriel Arturo Carpio
Gutierrez Flores Jose Luis
Karageozian Hampar L.
Karageozian Vicken H.
Kenney Maria Cristina
Ista Pharmaceuticals, Inc.
Knobbe Martens Olson & Bear LLP
Leith Patricia
LandOfFree
Hyaluronidase preparation for ophthalmic administration and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hyaluronidase preparation for ophthalmic administration and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hyaluronidase preparation for ophthalmic administration and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3435001